Compare

C21 Investments Inc. vs Mannatech Inc vs Niagen Bioscience, Inc. vs Natural Alternatives International Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearC21 Investments Inc.
CWLXF
Mannatech Inc
MTEX
Niagen Bioscience, Inc.
NAGE
Natural Alternatives International Inc
NAII
Year ended2026-03-312025-12-312025-12-312026-06-30
Revenue$32.61M$108.04M$129.42M$142.51M
Revenue growth (YoY)+8.3%-8.3%+29.9%+9.7%
Gross margin41.7%74.9%64.3%6.3%
Operating margin7.0%-0.4%12.6%-13.2%
Net margin-9.9%-14.1%13.4%-14.5%
Net income-$3.24M-$15.21M$17.38M-$20.70M
EPS (Diluted)-$0.03-$8.00$0.20-$3.43
Operating cash flow$1.36M-$2.96M$13.50M-$8.92M
Free cash flow$1.12M-$4.32Mn/a-$12.62M
Cash & equivalentsn/a$6.18Mn/a$7.39M
Total assets$54.42M$29.99M$106.41M$126.45M
Total liabilities$28.99M$35.22M$29.87M$76.49M
Shareholders' equity$25.43M-$5.22M$76.53M$49.96M
Return on year-end equity-12.8%n/a22.7%-41.4%
Shares outstanding117.84M1.90M79.71M6.27M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearC21 Investments Inc.Mannatech IncNiagen Bioscience, Inc.Natural Alternatives International Inc
Latest$32.61M
Ended 2026-03-31
$108.04M
Ended 2025-12-31
$129.42M
Ended 2025-12-31
$142.51M
Ended 2026-06-30
1 year earlier$30.12M
Ended 2025-03-31
$117.87M
Ended 2024-12-31
$99.60M
Ended 2024-12-31
$129.86M
Ended 2025-06-30
2 years earliern/a$131.96M
Ended 2023-12-31
$83.57M
Ended 2023-12-31
$113.80M
Ended 2024-06-30
3 years earliern/a$137.21M
Ended 2022-12-31
$72.05M
Ended 2022-12-31
$154.01M
Ended 2023-06-30
4 years earliern/a$159.76M
Ended 2021-12-31
$67.45M
Ended 2021-12-31
$170.97M
Ended 2022-06-30